Operating Segments (Tables)

12 Months Ended

Dec. 31, 2014

Operating Segments [Abstract]

Summary of segmental information

	For the Years Ended December 31,
	2014			2013
Revenues
Vaccines/BioDefense	$	6,756,388		$	3,003,822
BioTherapeutics		286,628			220,330
Total	$	7,043,016		$	3,224,152
Income (loss) from Operations
Vaccines/BioDefense	$	807,164		$	(1,666,130	)
BioTherapeutics		(7,674,381	)		(3,069,998	)
Corporate		(3,894,132	)		(2,420,414	)
Total	$	(10,761,349	)	$	(7,156,542	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	39,625		$	37,981
BioTherapeutics		199,196			190,033
Corporate		6,966			2,057
Total	$	245,787		$	230,071
Interest Income
Corporate	$	1,310		$	1,960
Stock-Based Compensation
Vaccines/BioDefense	$	114,920		$	80,432
BioTherapeutics		193,926			250,431
Corporate		411,304			472,197
Total	$	720,150		$	803,060

	As of December 31,
	2014		2013
Identifiable Assets
Vaccines/BioDefense	$	1,025,220	$	1,870,414
BioTherapeutics		204,308		386,721
Corporate		5,724,720		6,008,320
Total	$	6,954,248	$	8,265,455